-
Emergent to develop anthrax vaccine on HHS' behalf
WASHINGTON Emergent BioSolutions has landed a $51 million contract from the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority to develop a new anthrax vaccine.
In the first two years of the contract, Emergent will develop the final vaccine formulation and test its stability. HHS said it can extend the contract annually for up to three years to support scale-up and optimization for large-scale manufacturing, as well as additional animal studies needed to apply for Food and Drug Administration approval of the vaccine.
-
Study: Blood markers may help determine Type 2 diabetes risk
DALLAS A new study published in Circulation Research, a journal of the American Heart Association, found that blood levels of some ribonucleic acids — known as microRNAs — vary among those with Type 2 diabetes or those who develop the disease, compared with healthy people.
MicroRNA comprises shorter molecular chains than so-called messenger RNA, which takes the genetic information contained within the DNA and allows it to be turned into proteins with various functions, and previously has been linked to numerous diseases, including diabetes.